SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer

• SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC).

• The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.

• Also See: SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients.

• NEPC is an aggressive variant of prostate cancer. In up to 15%-20% of patients treated with hormonal therapies for prostate adenocarcinoma, small-cell prostate cancer may develop in later stages of prostate cancer progression.

• Median survival for NEPC patients whose cancer arose from prior prostate adenocarcinoma is estimated at only 5.4 months.

• The conversion to NEPC is associated with recurrent genetic lesions, including mutation or deletion of RB1 and TP53 and the overexpression and genomic amplification of MYCN.

• Price Action: SLS shares are up 0.83% at $3.35 on the last check Wednesday.

See more from Benzinga

• Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate

• Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.